DALLAS — Treatment modality for HPV-positive oropharyngeal squamous cell carcinoma varied considerably by facility type, according to study results. The findings — presented at American Head & Neck ...
Please provide your email address to receive an email when new articles are posted on . A triple-therapy combination extended OS compared with historical data among certain patients with advanced ...
PDS0101, an innovative immunotherapy, targets HPV-positive cancers, including recurrent or metastatic head and neck cancer with high-risk HPV16 infection. VERSATILE-002 Phase 2 clinical trial ...
A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Economic ...
HOUSTON - Oropharyngeal cancer patients whose tumors in the upper part of the throat test positively for the human papillomavirus (HPV) have better overall survival than patients with HPV-negative ...
Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show noninferiority versus standard care, which "reset the bar" for future trials of ...
An artificial intelligence (AI) pipeline developed at a Montreal-based cancer center has shown promise in detecting extranodal extension (ENE) from standard CT scans in patients with HPV-positive ...
The various manifestations of head and neck carcinomas rank sixth in frequency worldwide and are fatal for about half a million people every year. In a quarter of cases, head and neck squamous cell ...
A new research paper was published in Volume 16 of Genes & Cancer on August 6, 2025, titled "Epstein-Barr virus nuclear antigen 1 upregulates Derlin1 and PSMD10 expression in HeLa cells." In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback